FP01.04 BTCRC LUN19-396: Adjuvant Chemotherapy Plus Atezolizumab in Stage IB-IIIA Resected NSCLC and Clearance of ctDNA

Abstract

group. Nevertheless, the OS (72.5 months vs. 60.63 months, P ¼ 0.189) and DFS (13.7 months vs. 24.33 months, P ¼ 0.664) were not improved in EGFR-mutant patients with single-station N2 metastasis (Figure 1).Comparison of overall survivall (A,C,E) and disease-free survival (B,D,F) between the PORT and the non-PORT group. PORT¼postoperative radiotherapy. Conclusion: It is necessary for stage IIIA-N2 non-squamous NSCLC patients to receive PORT, especially for EGFR wild-type patients. Meanwhile, PORT can reduce local recurrence and metastasis in EGFR-mutant group, particularly in EGFR-mutant patients with multiple-station N2 metastasis. More prospective studies are needed to clarify the role of PORT in the EGFR-mutant IIIA-N2 non-squamous NSCLC patients.